LONDON (Alliance News) - GlaxoSmithKline PLC said Friday that it has made a submission to the European Medicines Agency seeking an additional indication for eltrombopag to cover the treatment of pediatric patients with chronic immune thrombocytopenic purpura who have had an insufficient response to corticosteroids or immunoglobulins.
The submission is based on results from its phase III PETIT2 study, and phase II PETIT study in paediatric chronic immune thrombocytopenic purpura.
Shares in GlaxoSmithKline are trading up 1.8% at 1,527.50 pence Friday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)